NO317934B1 - Fremgangsmate for beskyttelse og pavisning av en nukleinsyresekvens ved a anvende en nukleinsyreanalog, fremgangsmate for utforelse av en nukleinsyreamplifikasjon og fremgangsmate for opparbeidelse av reaksjonsprodukt derav. - Google Patents
Fremgangsmate for beskyttelse og pavisning av en nukleinsyresekvens ved a anvende en nukleinsyreanalog, fremgangsmate for utforelse av en nukleinsyreamplifikasjon og fremgangsmate for opparbeidelse av reaksjonsprodukt derav. Download PDFInfo
- Publication number
- NO317934B1 NO317934B1 NO19962331A NO962331A NO317934B1 NO 317934 B1 NO317934 B1 NO 317934B1 NO 19962331 A NO19962331 A NO 19962331A NO 962331 A NO962331 A NO 962331A NO 317934 B1 NO317934 B1 NO 317934B1
- Authority
- NO
- Norway
- Prior art keywords
- nucleic acid
- sequence
- complex
- group
- analogue
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 195
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 180
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 180
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 27
- 230000003321 amplification Effects 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims description 14
- 239000007795 chemical reaction product Substances 0.000 title claims description 5
- 238000013507 mapping Methods 0.000 title 1
- 101710163270 Nuclease Proteins 0.000 claims abstract description 17
- 238000009396 hybridization Methods 0.000 claims abstract description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- -1 hydroxy- Chemical class 0.000 claims description 13
- 230000000295 complement effect Effects 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 230000000593 degrading effect Effects 0.000 claims description 5
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 150000001371 alpha-amino acids Chemical class 0.000 claims description 4
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 125000006239 protecting group Chemical group 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 239000012625 DNA intercalator Substances 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 2
- 125000002723 alicyclic group Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000004925 denaturation Methods 0.000 claims description 2
- 230000036425 denaturation Effects 0.000 claims description 2
- 239000005547 deoxyribonucleotide Substances 0.000 claims description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 2
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 2
- 239000001177 diphosphate Substances 0.000 claims description 2
- 235000011180 diphosphates Nutrition 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000002777 nucleoside Substances 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 11
- 238000003556 assay Methods 0.000 abstract description 3
- 230000015556 catabolic process Effects 0.000 abstract description 2
- 238000006731 degradation reaction Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 33
- 239000003550 marker Substances 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000007790 solid phase Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical group CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 4
- 235000004936 Bromus mango Nutrition 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 4
- 241001093152 Mangifera Species 0.000 description 4
- 235000014826 Mangifera indica Nutrition 0.000 description 4
- 244000046052 Phaseolus vulgaris Species 0.000 description 4
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 4
- 235000009184 Spondias indica Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108060002716 Exonuclease Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 108010082683 kemptide Proteins 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000009920 chelation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- WIGDGIGALMYEBW-UHFFFAOYSA-N 2-[[2-[[2-[2-[[2-[[2-[(2-amino-4-methylpentanoyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoylamino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCN=C(N)N)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9324955A GB2285445A (en) | 1993-12-06 | 1993-12-06 | Protecting nucleic acids and methods of analysis |
PCT/EP1994/003973 WO1995015974A1 (en) | 1993-12-06 | 1994-11-30 | Protecting nucleic acids and methods of analysis |
Publications (3)
Publication Number | Publication Date |
---|---|
NO962331D0 NO962331D0 (no) | 1996-06-05 |
NO962331L NO962331L (no) | 1996-08-06 |
NO317934B1 true NO317934B1 (no) | 2005-01-10 |
Family
ID=10746180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19962331A NO317934B1 (no) | 1993-12-06 | 1996-06-05 | Fremgangsmate for beskyttelse og pavisning av en nukleinsyresekvens ved a anvende en nukleinsyreanalog, fremgangsmate for utforelse av en nukleinsyreamplifikasjon og fremgangsmate for opparbeidelse av reaksjonsprodukt derav. |
Country Status (16)
Country | Link |
---|---|
US (1) | US5861250A (da) |
EP (1) | EP0733062B1 (da) |
JP (1) | JPH09506255A (da) |
KR (1) | KR100221399B1 (da) |
AT (1) | ATE166066T1 (da) |
AU (1) | AU682563B2 (da) |
CA (1) | CA2177603C (da) |
DE (1) | DE69410291T2 (da) |
DK (1) | DK0733062T3 (da) |
ES (1) | ES2119370T3 (da) |
FI (1) | FI111266B (da) |
GB (1) | GB2285445A (da) |
IL (1) | IL111831A (da) |
NO (1) | NO317934B1 (da) |
WO (1) | WO1995015974A1 (da) |
ZA (1) | ZA949643B (da) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996027679A1 (en) | 1995-03-04 | 1996-09-12 | Boehringer Mannheim Gmbh | Modulation of the binding properties of nucleic acid binding partners |
EP0837884A2 (en) * | 1995-06-22 | 1998-04-29 | Dako A/S | Recombinant antibody capable of binding to pna/nucleic acid complexes |
WO1996014341A1 (en) * | 1995-06-22 | 1996-05-17 | Dako A/S | Monoclonal antibody capable of binding to pna/nucleic acid complexes |
US5677124A (en) * | 1996-07-03 | 1997-10-14 | Ambion, Inc. | Ribonuclease resistant viral RNA standards |
US5939262A (en) * | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
US5853990A (en) | 1996-07-26 | 1998-12-29 | Edward E. Winger | Real time homogeneous nucleotide assay |
DE19633436A1 (de) | 1996-08-20 | 1998-02-26 | Boehringer Mannheim Gmbh | Verfahren zum Nachweis von Nukleinsäuren unter Ermittlung der Masse |
US6617422B1 (en) | 1997-05-23 | 2003-09-09 | Peter Nielsen | Peptide nucleic acid monomers and oligomers |
WO1999034014A2 (en) * | 1997-12-23 | 1999-07-08 | Roche Diagnostics Gmbh | A method for the determination of a nucleic acid |
WO1999036571A2 (en) * | 1998-01-13 | 1999-07-22 | Biochip Technologies Gmbh | Method for the detection or nucleic acid of nucleic acid sequences |
DK1137807T3 (da) * | 1998-12-08 | 2005-01-24 | Boston Probes Inc | Fremgangsmåder, kits og sammensætninger til identifikation af nukleinsyrer, der er elektrostatisk bundet til matrixer |
WO2000034521A1 (en) * | 1998-12-08 | 2000-06-15 | Boston Probes, Inc. | Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices |
CA2366289A1 (en) * | 1999-03-25 | 2000-09-28 | Radoje T. Drmanac | Solution-based methods and materials for sequence analysis by hybridization |
US7816098B2 (en) * | 2000-01-31 | 2010-10-19 | Sense Proteomic Limited | Methods of making and using a protein array |
EP1290217A2 (en) * | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
CA2402319A1 (en) | 2000-03-14 | 2001-09-20 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
US6962906B2 (en) * | 2000-03-14 | 2005-11-08 | Active Motif | Oligonucleotide analogues, methods of synthesis and methods of use |
US20040014644A1 (en) * | 2000-03-14 | 2004-01-22 | Vladimir Efimov | Oligonucleotide analogues and methods of use for modulating gene expression |
GB0406864D0 (en) | 2004-03-26 | 2004-04-28 | Qiagen As | Nucleic acid sequencing |
US20080268451A1 (en) * | 2007-03-30 | 2008-10-30 | Bruce Seligmann | Measurement of an insoluble analyte in a sample |
US20100129902A1 (en) | 2008-11-24 | 2010-05-27 | Erhard Ralf Schoenbrunner | Replication Stable and RNase Resistant Chimeras of Pestivirus with Insertion in 3' Nontranslated Region (3'NTR) |
EP2496715B1 (en) * | 2009-11-03 | 2016-01-27 | HTG Molecular Diagnostics, Inc. | Quantitative nuclease protection sequencing (qnps) |
WO2012151111A1 (en) | 2011-05-04 | 2012-11-08 | Htg Molecular Diagnostics, Inc. | Quantitative nuclease protection assay (qnpa) and sequencing (qnps) improvements |
KR20160106684A (ko) | 2014-01-10 | 2016-09-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 히드록시포름아미드 유도체 및 그의 용도 |
US10689689B2 (en) | 2015-12-28 | 2020-06-23 | Roche Molecular Systems, Inc. | Generic method for the stabilization of specific RNA |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4800159A (en) * | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5578468A (en) * | 1987-08-10 | 1996-11-26 | Duke University | Site-specific RNA cleavage |
US5539082A (en) * | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
DK51092D0 (da) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
-
1993
- 1993-12-06 GB GB9324955A patent/GB2285445A/en not_active Withdrawn
-
1994
- 1994-11-30 JP JP7515942A patent/JPH09506255A/ja active Pending
- 1994-11-30 DE DE69410291T patent/DE69410291T2/de not_active Expired - Lifetime
- 1994-11-30 WO PCT/EP1994/003973 patent/WO1995015974A1/en active IP Right Grant
- 1994-11-30 KR KR1019960703043A patent/KR100221399B1/ko not_active IP Right Cessation
- 1994-11-30 EP EP95903782A patent/EP0733062B1/en not_active Expired - Lifetime
- 1994-11-30 ES ES95903782T patent/ES2119370T3/es not_active Expired - Lifetime
- 1994-11-30 IL IL11183194A patent/IL111831A/xx not_active IP Right Cessation
- 1994-11-30 CA CA002177603A patent/CA2177603C/en not_active Expired - Lifetime
- 1994-11-30 AT AT95903782T patent/ATE166066T1/de not_active IP Right Cessation
- 1994-11-30 DK DK95903782T patent/DK0733062T3/da active
- 1994-11-30 AU AU12729/95A patent/AU682563B2/en not_active Expired
- 1994-12-05 ZA ZA949643A patent/ZA949643B/xx unknown
-
1996
- 1996-06-05 FI FI962340A patent/FI111266B/fi not_active IP Right Cessation
- 1996-06-05 NO NO19962331A patent/NO317934B1/no not_active IP Right Cessation
- 1996-06-06 US US08/659,529 patent/US5861250A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US5861250A (en) | 1999-01-19 |
ES2119370T3 (es) | 1998-10-01 |
WO1995015974A1 (en) | 1995-06-15 |
GB9324955D0 (en) | 1994-01-26 |
IL111831A (en) | 2000-12-06 |
NO962331D0 (no) | 1996-06-05 |
CA2177603A1 (en) | 1995-06-15 |
FI111266B (fi) | 2003-06-30 |
IL111831A0 (en) | 1995-01-24 |
KR100221399B1 (ko) | 1999-10-01 |
AU1272995A (en) | 1995-06-27 |
EP0733062B1 (en) | 1998-05-13 |
ZA949643B (en) | 1996-06-05 |
NO962331L (no) | 1996-08-06 |
DK0733062T3 (da) | 1999-03-15 |
FI962340A (fi) | 1996-06-05 |
AU682563B2 (en) | 1997-10-09 |
KR960706504A (ko) | 1996-12-09 |
EP0733062A1 (en) | 1996-09-25 |
DE69410291D1 (de) | 1998-06-18 |
JPH09506255A (ja) | 1997-06-24 |
FI962340A0 (fi) | 1996-06-05 |
GB2285445A (en) | 1995-07-12 |
CA2177603C (en) | 2000-07-18 |
DE69410291T2 (de) | 1998-10-29 |
ATE166066T1 (de) | 1998-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO317934B1 (no) | Fremgangsmate for beskyttelse og pavisning av en nukleinsyresekvens ved a anvende en nukleinsyreanalog, fremgangsmate for utforelse av en nukleinsyreamplifikasjon og fremgangsmate for opparbeidelse av reaksjonsprodukt derav. | |
FI110694B (fi) | Nukleiinihappoanalogien käyttö nukleiinihappoamplifikaation inhibiitiossa | |
EP0730602B1 (en) | Nucleic acid analogs with a chelating functionality | |
US6949343B2 (en) | Methods, kits and compositions pertaining to PNA Molecular Beacons | |
US6015666A (en) | Rapid DNA test for detecting quinolone-resistant Staphylococcus aureus pathogens in clinical material | |
AU2006302044B2 (en) | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx | |
US6169169B1 (en) | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis | |
US20110003712A1 (en) | Methods, Kits and Compositions for the Identification of Nucleic Acids Electrostatically Bound to Matrices | |
US7560232B2 (en) | Methods of capturing, detecting and quantifying RNA:DNA hybrids and a modified RNase H useful therein | |
JPH06209797A (ja) | カンジダ・アルビカンス(Candida albicans)の診断的研究のための特異的遺伝子のプローブ | |
KR100196083B1 (ko) | 핵산유사체-펩티드 키메라를 표지화시키는 방법 | |
EP3746567A1 (en) | Composition and methods for affinity directed enrichment of rare species | |
JPH11127876A (ja) | 小三本鎖形成pnaオリゴ | |
EP0815259B1 (en) | Modulation of the binding properties of nucleic acid binding partners | |
AU2013200217B2 (en) | Sequences for detection and identification of methicillin-resistant Staphylococcus aureus (MRSA) of MREJ types xi to xx | |
EP1137807B1 (en) | Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices | |
JP2000300268A (ja) | 核酸の測定方法及びそのためのキット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |